A Study To Assess the Effects Of PF-04457845 On BOLD fMRI In Subjects With Post Traumatic Stress Disorder
Public ClinicalTrials.gov record NCT02216097. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, Placebo Controlled, Parallel Group Phase 2 Study To Assess Effects Of Pf 04457845 On Bold Functional Mri In Subjects With Ptsd
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate proof of mechanism of PF-04457845, using a well-established neuroimaging paradigm including behavioral tasks selected to activate neuro-circuitry relevant to Post Traumatic Stress Disorder. It is hypothesized that PF-04457845 will modulate the Blood-oxygen-level dependent Functional Magnetic Resonance Imaging signal from the relevant neuro-circuits in patients with Post Traumatic Stress Disorder.
Study identification
- NCT ID
- NCT02216097
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 14 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 60 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2014
- Primary completion
- Feb 28, 2015
- Completion
- Feb 28, 2015
- Last update posted
- Jun 28, 2016
2014 – 2015
United States locations
- U.S. sites
- 3
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical and Translational Science Institute (CTSI) | New York | New York | 10016 | — |
| NYU CTSI Research Pharmacy (Drug Shipment Address) | New York | New York | 10016 | — |
| NYU School of Medicine | New York | New York | 10016 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Post-Traumatic Stress Disorder trials
Other public records listing Post-Traumatic Stress Disorder. Sorted by last update posted; newest first. Not a recommendation.
- NCT05541406: Efficacy of a Multi-level School Intervention for LGBTQ Youth Active, not recruiting
- NCT07732374: Long-Term Outcomes Following HBOT Recruiting
- NCT05478759: Innovative Multimodal and Attention Training to Improve Emotion Communication in Veterans With TBI and PTSD Active, not recruiting
- NCT07715799: Noninvasive Brain Stimulation Combined With Written Exposure Therapy for PTSD in Military Personnel With TBI Not yet recruiting
- NCT07714083: Cognitive Processing Therapy for Posttraumatic Stress Disorder and Co-occurring Lived Experience Stress Not yet recruiting
- NCT07316088: Determining the Potential for Efficacy of OTX-601 in Reducing PTSD Symptoms Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02216097, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 28, 2016 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02216097 live on ClinicalTrials.gov.